JMP Securities analyst Silvan Tuerkcan maintained a Hold rating on Turning Point Therapeutics (TPTX – Research Report) today. The company’s shares closed yesterday at $75.04.
Tuerkcan covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Mirati Therapeutics, and MacroGenics. According to TipRanks, Tuerkcan has an average return of 4.3% and a 42.86% success rate on recommended stocks.
Currently, the analyst consensus on Turning Point Therapeutics is a Hold with an average price target of $73.00.
See the top stocks recommended by analysts >>
Based on Turning Point Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $429 thousand and a GAAP net loss of $74.45 million. In comparison, last year the company earned revenue of $25.21 million and had a GAAP net loss of $35.5 million
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TPTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. It focuses on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.
Read More on TPTX:
- JMP Securities Sticks to Its Buy Rating for Sutro Biopharma (STRO)
- JMP Securities Sticks to Their Buy Rating for Minerva Neurosciences (NERV)
- BTIG Keeps Their Buy Rating on Organogenesis Holdings (ORGO)
- Analysts Offer Insights on Technology Companies: Trade Desk (TTD) and Arteris (AIP)
- Alkaline Fuel Cell Power Announces Development of Fuel Cells for Off-Grid and Back-Up Generator Markets
